Clinical trials: Defects
Stroke, Patent Foramen Ovale
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO…
- Conditions
- Stroke, Patent Foramen Ovale, PFO
- Trial name
- OCCLUFLEX (NCT05069558)
- Testing
- Investigational PFO Closure Device, Standard of Care PFO Closure Device
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 450 people
- Sponsor
- Occlutech International AB
Turner Syndrome
A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome
This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children of Turner syndrome (TS), preliminarily evaluate its safety and efficacy and provide scientific and…
- Trial name
- NCT03189160
- Testing
- PEG-rhGH low dose, PEG-rhGH high dose, Non-treatment control group
- Where
- 9 sites in China
- Volunteers
- 180 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Secundum Atrial Septal Defects
Occlutech Septal Occluder (Figulla Flex II) Study
The objectives of the study are: To determine the efficacy of the Figulla Flex II device compared with that of the Amplatzer ASO device for transcatheter closure of secundum atrial septal defects To determine the safety of the…
- Trial name
- NCT04488120
- Testing
- transcatheter closure of secundum atrial septal defects in patients
- Volunteers
- 175 people
- Sponsor
- Occlutech International AB
Long QT Syndrome
Phase 1 Study of LQT-1213 in Healthy Adults
This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD).
- Trial name
- NCT05759962
- Testing
- LQT-1213
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Thryv Therapeutics, Inc.
PTA (Percutaneous Transluminal Angioplasty ), Femoropopliteal Artery Disease
Clinical Outcomes of GENOSS PCB for Femoropopliteal Artery Disease
The GENOSS PCB study aims to evaluate the safety and efficacy of a Paclitaxel-coated PTA Balloon Catheter(GENOSS® PCB) in patients with the femoropopliteal artery disease.
- Trial name
- GENOSS PCB (NCT07399080)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Genoss Co., Ltd.
Foramen Ovale, Patent
The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness
The primary objective of this study is to demonstrate the safety and efficacy of the PFX Closure System when utilized for patent foramen ovale (PFO) in patients suffering from cryptogenic stroke (undetermined cause of stroke)…
- Trial name
- NCT00196040
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Cierra
Persistent Corneal Epithelial Defect
A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
Capellion is a Phase 2 trial comparing TP-06 2.0% with Vehicle in up to 32 adults with persistent corneal epithelial defects. Participants will receive treatment for 8 weeks and be followed for 2 additional weeks to assess…
- Trial name
- Capellion (NCT07886268)
- Testing
- TP-06, Vehicle of TP-06
- Where
- 14 sites in United States, Dominican Republic and 2 more
- Volunteers
- 32 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Congenital Heart Disease, Congenital Heart Disease (CHD)
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Starlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the Lifeline Ductus Arteriosus Stent System.
- Trial name
- NCT07114718
- Testing
- Ductus Arteriosus Stent
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Starlight Cardiovascular Inc
Burn, Thermal
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements
About 70 participants will be enrolled. They will have complex skin defects because of burns caused by heat. The burns will: be on 3-49% of the participant's total body surface area (TBSA) require surgery for skin replacement…
- Trial name
- NCT03005106
- Testing
- StrataGraft Skin Tissue, Autograft
- Where
- 16 sites in United States
- Volunteers
- 71 people
- Sponsor
- Stratatech, a Mallinckrodt Company
Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
The goal of this clinical trial is to test IC14 (atibuclimab) in patients with arrhythmogenic cardiomyopathy (ACM) and who have an implantable cardoverter/defibrillator in place.
- Conditions
- Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy 1, Arrhythmogenic Cardiomyopathy
- Trial name
- NCT06275893
- Testing
- IC14
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Implicit Bioscience
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Cartilage Repair
Post Market Study of DeNovo NT, Natural Tissue Graft
The purpose of this post market study is to evaluate surgical implantation technique and the quality of repair of the cartilage defect with particulated juvenile cartilage in the human knee joint.
- Trial name
- NCT00791245
- Testing
- Particulated Juvenile Cartilage Allograft
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Zimmer Orthobiologics, Inc.
Bone Augmentation, Bone Grafts
Filling Bone Defects/Voids With Autologous BonoFill-II for Maxillofacial Bone Regeneration
The purpose of this clinical study is to evaluate the safety and the efficacy of BonoFill-II as a bone filler containing the patient's own (autologous) adipose (fat) tissue-derived cells in reconstructing bone in two clinical…
- Trial name
- NCT02842619
- Testing
- BonoFill-II
- Where
- Israel
- Volunteers
- 27 people
- Sponsor
- BonusBio Group Ltd
Turner's Syndrome
A Clinical Study to Assess the Efficacy and Safety of DA-3002
A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.
- Trial name
- NCT01813630
- Testing
- DA-3002, Genotropin®
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Dong-A ST Co., Ltd.
Cardiac Defect, Cardiac Anomaly
Post Market Observational Retrospective Study of Glycar Bovine Pericardial Patch (CIP-003)
The overall purpose of this observational Post Market Clinical Follow Up (PMCF) study is to ensure continued acceptability of the benefit risk ratio by assessment of safety and performance, in patients undergoing cardiovascular…
- Conditions
- Cardiac Defect, Cardiac Anomaly, Pericardial Defect
- Trial name
- NCT06088680
- Testing
- Glycar Pericardial Patch
- Where
- South Africa
- Volunteers
- 50 people
- Sponsor
- GLYCAR SA (Pty) Ltd
Structural Cardiac Defects
Three-dimensional (3D) Holographic Display for Ultrasound-Guided Structural Heart Disease Procedures
This study is intended to evaluate the use of the holographic display of 3D images acquired during ultrasound based cardiac procedures and to assess the clinical use of the HOLOSCOPE-i, in providing 3D spatial understanding to…
- Trial name
- NCT05514626
- Testing
- 3D Holographic Display
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- RealView Imaging
Patent Ductus Arteriosus
AMPLATZER Duct Occluder II Additional Sizes
The ADO II AS Study is a single arm, prospective, multicenter, nonrandomized clinical investigation to characterize the safety and effectiveness of the ADO II AS device in patients with a patent ductus arteriosus (PDA).
- Trial name
- ADO II AS (NCT03055858)
- Testing
- ADO II AS (PDA closure)
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Heart Defects, Congenital, Hypertension, Pulmonary
Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery
This clinical trial will determine the safety and effectiveness of intravenous L-citrulline in children undergoing cardiopulmonary bypass during heart surgery.
- Trial name
- NCT00335244
- Testing
- L-citrulline
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Asklepion Pharmaceuticals, LLC
Articular Cartilage Disorder, Degeneration; Articular Cartilage
Chondrofix Osteochondral Allograft Prospective Study
The overall study objective is to evaluate Chondrofix Osteochondral Allograft ("Chondrofix") for the repair of osteochondral lesions in the knee.
- Conditions
- Articular Cartilage Disorder, Degeneration; Articular Cartilage, Chronic Cartilage Injury, Acute Cartilage Injury
- Trial name
- NCT01410136
- Testing
- Chondrofix Osteochondral Allograft
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Zimmer Orthobiologics, Inc.
Bone Defect
FlexiOss® - Efficacy, Safety and Long-term (Radiological and Clinical) Outcomes During Comprehensive Care Continuum of Implanted Biocomposite for Bone Regeneration.
The aim of this clinical study is to evaluate the efficacy, safety and long-term (radiological and clinical) outcomes during comprehensive care continuum of implanted biocomposite for bone regeneration FlexiOss® compared to the…
- Trial name
- FlexiOssOT (NCT07209033)
- Testing
- FlexiOss®, Allogenic human bone grafting
- Where
- 2 sites in Poland
- Volunteers
- 80 people
- Sponsor
- Medical Inventi S.A.